|
SSR1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.74549996678763E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.10342854245482E-12 |
| Normal-vs-Stage2 |
4.01370000000512E-05 |
| Normal-vs-Stage3 |
4.05209976683807E-10 |
| Normal-vs-Stage4 |
1.05059960731069E-10 |
| Stage1-vs-Stage2 |
3.108400E-01 |
| Stage1-vs-Stage3 |
1.428400E-01 |
| Stage1-vs-Stage4 |
5.460400E-02 |
| Stage2-vs-Stage3 |
5.434200E-02 |
| Stage2-vs-Stage4 |
1.777550E-02 |
| Stage3-vs-Stage4 |
4.357800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.7351000070629E-10 |
| Normal-vs-AfricanAmerican |
2.801000E-03 |
| Normal-vs-Asian |
1.44050005257412E-09 |
| Caucasian-vs-AfricanAmerican |
8.520000E-02 |
| Caucasian-vs-Asian |
6.700200E-01 |
| AfricanAmerican-vs-Asian |
1.395370E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.10349532131704E-12 |
| Normal-vs-Female |
1.91391347215131E-12 |
| Male-vs-Female |
2.538400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.13250520072938E-11 |
| Normal-vs-Age(41-60Yrs) |
1.15400000666455E-09 |
| Normal-vs-Age(61-80Yrs) |
3.94260002423152E-09 |
| Normal-vs-Age(81-100Yrs) |
1.449960E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.938800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.591800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.167200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.011600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.101800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.513000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.448770E-01 |
| Classical-VS-Follicular |
3.789400E-01 |
| Classical-VS-Other |
1.008800E-01 |
| Classical-VS-Normal |
6.59340004816045E-09 |
| Tall-VS-Follicular |
6.070000E-02 |
| Tall-VS-Other |
3.613400E-01 |
| Tall-VS-Normal |
7.85819997961568E-09 |
| Follicular-VS-Other |
1.406770E-01 |
| Follicular-VS-Normal |
2.75819999995264E-06 |
| Other-VS-Normal |
3.389700E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.62490029712126E-10 |
| Normal-vs-N1 |
1.49179557595858E-11 |
| N0-vs-N1 |
4.720400E-03 |
|
|
